LC-TD-05
LC-TD-05 is a non-covalent inhibitor of TEAD1, TEAD2 and TEAD4, with IC50 values of 116.6 nM, 168.7 nM and 68.3 nM, respectively; it shows weak activity against TEAD3, with a human IC50 of 1261.0 nM. LC-TD-05 induces apoptosis in hepatocellular carcinoma cells. LC-TD-05 can be used for the research of hepatocellular carcinoma.
For research use only. We do not sell to patients.
- Formula: C27H23F3N4O2
- Molecular Weight:492.49
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All YAP Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
TEAD4 68.3 nM (IC50) |
TEAD1 116.6 nM (IC50) |
TEAD2 168.7 nM (IC50) |
TEAD3 1261.0 nM (IC50) |
In Vitro
LC-TD-05 (72 h) selectively inhibits the proliferation of HCC LM3, SK-HEP-1, HepG2 and Huh7 cells, with IC50 values of 248 nM, 964 nM, 7.108 μM and 4.603 μM, respectively. It exhibits extremely low cytotoxicity toward non-tumorigenic HEK293T and THLE-2 cells[1].
LC-TD-05 (3 μM; 10-14 d) potently inhibits colony formation of HCC LM3 cells[1].
LC-TD-05 (0.3-10 μM; 3 h) downregulates the mRNA expression of TEAD target genes CTGF and CYR61 in HCC LM3 cells in a dose-dependent manner[1].
LC-TD-05 (3-10 μM; 72 h) dose-dependently induces apoptosis in hepatocellular carcinoma LM3 cells[1].
LC-TD-05 inhibits TEAD-associated transcriptional programs in HCC LM3 cells, including downregulation of cell cycle progression genes and canonical TEAD target genes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCC LM3 cells
-
Concentration:3 μM
-
Incubation Time:10-14 days
-
Result:Significantly reduced the number of colonies formed by HCC LM3 cells compared to DMSO control.
-
Cell Line:HCC LM3 cells
-
Concentration:0.3, 1, 3 and 10 μM
-
Incubation Time:3 hours
-
Result:Significantly downregulated the mRNA expression of CTGF and CYR61 in a dose-dependent manner, with maximal suppression at 10 μM.
-
Cell Line:HCC LM3 cells
-
Concentration:3 and 10 μM
-
Incubation Time:72 hours
-
Result:Induced a dose-dependent increase in the proportion of apoptotic HCC LM3 cells, with significant elevation at 3 μM and 10 μM compared to DMSO control.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (male, 4-6 weeks old)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; once daily; 17 days
-
Result:Achieved a tumor growth inhibition (TGI) of 75%.
Markedly reduced tumor weights compared to vehicle controls.
Showed no significant change in body weight relative to the vehicle group.
Reduced protein and transcript levels of the TEAD target genes CTGF and CYR61 in treated tumor tissues.
Chemical Information
-
Molecular Weight 492.49
-
Formula C27H23F3N4O2
-
SMILES
O=C(N1CCN(C(C2=CC=CC3=C2C=CN3C4=CC=C(C(F)(F)F)C=C4)=O)CC1)NC5=CC=CC=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)